CL2022000790A1 - Método para tratar vih con cabotegravir y rilpivirina - Google Patents
Método para tratar vih con cabotegravir y rilpivirinaInfo
- Publication number
- CL2022000790A1 CL2022000790A1 CL2022000790A CL2022000790A CL2022000790A1 CL 2022000790 A1 CL2022000790 A1 CL 2022000790A1 CL 2022000790 A CL2022000790 A CL 2022000790A CL 2022000790 A CL2022000790 A CL 2022000790A CL 2022000790 A1 CL2022000790 A1 CL 2022000790A1
- Authority
- CL
- Chile
- Prior art keywords
- cabotegravir
- rilpivirine
- treat hiv
- human
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908995P | 2019-10-01 | 2019-10-01 | |
| US201962908882P | 2019-10-01 | 2019-10-01 | |
| US202063037782P | 2020-06-11 | 2020-06-11 | |
| US202063052214P | 2020-07-15 | 2020-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022000790A1 true CL2022000790A1 (es) | 2022-11-25 |
Family
ID=72826936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022000790A CL2022000790A1 (es) | 2019-10-01 | 2022-03-30 | Método para tratar vih con cabotegravir y rilpivirina |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20220347174A1 (enExample) |
| EP (1) | EP4037661A1 (enExample) |
| JP (1) | JP7791083B2 (enExample) |
| KR (1) | KR20220074880A (enExample) |
| CN (2) | CN114502166A (enExample) |
| AU (1) | AU2020358156B2 (enExample) |
| CA (1) | CA3155587A1 (enExample) |
| CL (1) | CL2022000790A1 (enExample) |
| IL (1) | IL290716A (enExample) |
| MX (1) | MX2022003945A (enExample) |
| WO (1) | WO2021064618A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3103522C (en) | 2018-07-16 | 2023-11-21 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| WO2023222755A1 (en) * | 2022-05-17 | 2023-11-23 | Janssen Sciences Ireland Unlimited Company | Treatment or prevention of hiv infection |
| TW202408526A (zh) * | 2022-05-17 | 2024-03-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 治療或預防hiv感染(一) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122000A1 (en) | 1981-01-07 | 2004-06-24 | Vertex Pharmaceuticals Incorporated. | Inhibitors of aspartyl protease |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| US6319946B1 (en) | 1999-02-12 | 2001-11-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of aspartyl protease |
| PT3366278T (pt) | 2006-06-23 | 2024-10-21 | Janssen Sciences Ireland Unlimited Co | Suspensões aquosas de tmc278 |
| KR101811314B1 (ko) * | 2009-09-22 | 2017-12-26 | 얀센 알 앤드 디 아일랜드 | Ｈｉｖ 감염의 치료 및 예방 |
| EP3351249A1 (en) | 2010-01-27 | 2018-07-25 | VIIV Healthcare Company | Antiviral therapy |
| CN104902905A (zh) | 2012-12-14 | 2015-09-09 | 葛兰素史克有限责任公司 | 药物组合物 |
| US20160067255A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
| EA201790495A1 (ru) | 2014-09-26 | 2017-09-29 | Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед | Фармацевтические композиции длительного действия |
| WO2019016732A1 (en) * | 2017-07-21 | 2019-01-24 | Viiv Healthcare Company | REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS |
| CN109568328A (zh) * | 2017-09-29 | 2019-04-05 | 重庆药友制药有限责任公司 | 一种用于预防和治疗hiv感染的药物组合物 |
| EP3986561B1 (en) * | 2019-06-19 | 2024-02-14 | VIIV Healthcare UK (No.5) Limited | Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication |
-
2020
- 2020-10-01 AU AU2020358156A patent/AU2020358156B2/en active Active
- 2020-10-01 KR KR1020227010390A patent/KR20220074880A/ko not_active Ceased
- 2020-10-01 US US17/763,076 patent/US20220347174A1/en not_active Abandoned
- 2020-10-01 EP EP20789687.9A patent/EP4037661A1/en active Pending
- 2020-10-01 CN CN202080069721.1A patent/CN114502166A/zh active Pending
- 2020-10-01 JP JP2022520291A patent/JP7791083B2/ja active Active
- 2020-10-01 WO PCT/IB2020/059185 patent/WO2021064618A1/en not_active Ceased
- 2020-10-01 CN CN202410349180.8A patent/CN118416069A/zh active Pending
- 2020-10-01 MX MX2022003945A patent/MX2022003945A/es unknown
- 2020-10-01 CA CA3155587A patent/CA3155587A1/en active Pending
-
2022
- 2022-02-17 IL IL290716A patent/IL290716A/en unknown
- 2022-03-30 CL CL2022000790A patent/CL2022000790A1/es unknown
-
2025
- 2025-06-04 US US19/227,609 patent/US12636286B2/en active Active
- 2025-06-04 US US19/227,593 patent/US12636285B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7791083B2 (ja) | 2025-12-23 |
| AU2020358156B2 (en) | 2024-06-06 |
| IL290716A (en) | 2022-04-01 |
| EP4037661A1 (en) | 2022-08-10 |
| CN118416069A (zh) | 2024-08-02 |
| WO2021064618A1 (en) | 2021-04-08 |
| JP2022550828A (ja) | 2022-12-05 |
| US12636285B2 (en) | 2026-05-26 |
| US12636286B2 (en) | 2026-05-26 |
| CN114502166A (zh) | 2022-05-13 |
| US20220347174A1 (en) | 2022-11-03 |
| CA3155587A1 (en) | 2021-04-08 |
| AU2020358156A1 (en) | 2022-04-21 |
| US20250302829A1 (en) | 2025-10-02 |
| US20250302830A1 (en) | 2025-10-02 |
| MX2022003945A (es) | 2022-04-25 |
| KR20220074880A (ko) | 2022-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| CL2018002807A1 (es) | Métodos de tratamiento de cánceres pediátricos. | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| MX2020001732A (es) | Tratamiento de las afecciones del sistema nervioso central. | |
| CO2017004715A2 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos | |
| MX2022000143A (es) | Metodos novedosos. | |
| MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
| CL2019000935A1 (es) | Composición farmacéutica, métodos para tratamiento y usos de la misma. | |
| MX2019003703A (es) | Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23. | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| MX2017015938A (es) | Inhibidores de ezh2 para el tratar linfomas. | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| MX2024002581A (es) | Lou064 para el tratamiento de la esclerosis multiple. | |
| MX2022003945A (es) | Metodo para tratar vih con cabotegravir y rilpivirina. | |
| MX2019009190A (es) | Uso de gaboxadol en el tratamiento de tinnitus. | |
| MX2019014024A (es) | Tratamiento de los trastornos depresivos. | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| CL2019002325A1 (es) | Combinaciones farmacéuticas para tratar cáncer. | |
| CL2021001623A1 (es) | Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| CO2020010013A2 (es) | Terapia de combinación para tratar o prevenir el cáncer | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| CL2021000107A1 (es) | Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma |